Back Into Spark Therapeutics

Today, Roche (Ticker: RHHBY) received approval for its acquisition of Spark Therapeutics (Ticker: ONCE) from Britain’s Competition and Markets Authority (CMA). This was the catalysts I was looking for… I went back into Sparks today via common stock at an average price of $113.68 comprising of ~ 40% of my portfolio. I like the risk and reward at this point as the FTC was working close with Britain’s CMA during the review process. I’m modeling a year end close, which equates to a potential ~ 16% annualized rate of return. Not bad considering this is close to the finish line.